Cargando…
1633P Why do cancer clinical trials (CT) discontinue prematurely in the era of COVID-19?
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454356/ http://dx.doi.org/10.1016/j.annonc.2021.08.1626 |
| _version_ | 1784570471874822144 |
|---|---|
| author | Iannantuono, G.M. Torino, F. Strigari, L. Capotondi, B. Dell'Aria, F. Flaminio, V. Guerriero, S. Parisi, G. Rosenfeld, R. Amodio, F. Creso, B. Filomeno, L. Mastrobattista, F. Meacci, A. Palumbo, F.E. Santurri, L. Sganga, S. Roselli, M. |
| author_facet | Iannantuono, G.M. Torino, F. Strigari, L. Capotondi, B. Dell'Aria, F. Flaminio, V. Guerriero, S. Parisi, G. Rosenfeld, R. Amodio, F. Creso, B. Filomeno, L. Mastrobattista, F. Meacci, A. Palumbo, F.E. Santurri, L. Sganga, S. Roselli, M. |
| author_sort | Iannantuono, G.M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8454356 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84543562021-09-21 1633P Why do cancer clinical trials (CT) discontinue prematurely in the era of COVID-19? Iannantuono, G.M. Torino, F. Strigari, L. Capotondi, B. Dell'Aria, F. Flaminio, V. Guerriero, S. Parisi, G. Rosenfeld, R. Amodio, F. Creso, B. Filomeno, L. Mastrobattista, F. Meacci, A. Palumbo, F.E. Santurri, L. Sganga, S. Roselli, M. Ann Oncol Article European Society for Medical Oncology. Published by Elsevier Ltd. 2021-09 2021-09-21 /pmc/articles/PMC8454356/ http://dx.doi.org/10.1016/j.annonc.2021.08.1626 Text en Copyright © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Iannantuono, G.M. Torino, F. Strigari, L. Capotondi, B. Dell'Aria, F. Flaminio, V. Guerriero, S. Parisi, G. Rosenfeld, R. Amodio, F. Creso, B. Filomeno, L. Mastrobattista, F. Meacci, A. Palumbo, F.E. Santurri, L. Sganga, S. Roselli, M. 1633P Why do cancer clinical trials (CT) discontinue prematurely in the era of COVID-19? |
| title | 1633P Why do cancer clinical trials (CT) discontinue prematurely in the era of COVID-19? |
| title_full | 1633P Why do cancer clinical trials (CT) discontinue prematurely in the era of COVID-19? |
| title_fullStr | 1633P Why do cancer clinical trials (CT) discontinue prematurely in the era of COVID-19? |
| title_full_unstemmed | 1633P Why do cancer clinical trials (CT) discontinue prematurely in the era of COVID-19? |
| title_short | 1633P Why do cancer clinical trials (CT) discontinue prematurely in the era of COVID-19? |
| title_sort | 1633p why do cancer clinical trials (ct) discontinue prematurely in the era of covid-19? |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454356/ http://dx.doi.org/10.1016/j.annonc.2021.08.1626 |
| work_keys_str_mv | AT iannantuonogm 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 AT torinof 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 AT strigaril 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 AT capotondib 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 AT dellariaf 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 AT flaminiov 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 AT guerrieros 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 AT parisig 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 AT rosenfeldr 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 AT amodiof 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 AT cresob 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 AT filomenol 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 AT mastrobattistaf 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 AT meaccia 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 AT palumbofe 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 AT santurril 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 AT sgangas 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 AT rosellim 1633pwhydocancerclinicaltrialsctdiscontinueprematurelyintheeraofcovid19 |